Skip to main content
P&T COMMUNITY
Register
Sign in
Search form
Search
Home
News
P&T
Current issue
Past issues
Contact us
Digital Edition
Subscribe
P&T TV
Dr. David B. Nash
Meeting Highlights
Authors
About
Contact Us
News
P&T Journal
Formulary Kits
INGREZZA®
(valbenazine) tablets
KEDRAB™
(Rabies Immune Globulin [Human])
LOKELMA™
(sodium zirconium cyclosilicate) 10 g for oral suspension
PERSERIS™
(risperidone) for extended-release injectable suspension
SUBLOCADE™
(buprenorphine extended-release) Injection for Subcutaneous Use (CIII)
Please
click
for full Prescribing Information, including Boxed Warning.
You are here
Home
News by month %2 2017
News by month October 2017
PTCommunity News October 2017
Positive Phase 3 Results for Dupilumab in Severe Steroid-Dependent Asthma
Companies, Medications Added in Generic-Drug Antitrust Suit
Drug-Pricing Watchdog Gets Funding to Expand Efforts
Study: Lethal Dangers Lurk Even After Opioid Overdose Rescue
FDA Approves New Treatment for Mantle Cell Lymphoma
Haegarda Shows 98% Median Reduction in Hereditary Angioedema Attacks Per Month in Study
New Data: Children and Adolescents With MS Had an 82% Lower Relapse Rate With Fingolimod
Orphan Drug Designation Granted to MM-121 for the Treatment of Heregulin-Positive Non–Small-Cell Lung Cancer
FDA Approves New Dosing for Rivaroxaban to Reduce the Continued Risk of Venous Thromboembolism
U.S. Moves to Revoke Claim That Soy Protein Protects the Heart
Breakthrough Therapy Status for Hemophilia A Treatment
Intravenous Formulation of Varubi Wins FDA Approval
Cholesterol Levels Falling Among U.S. Adults, CDC Says
FDA Won’t Approve Ataluren; PTC Therapeutics to Appeal
ACIP Recommends Shingrix Over Zostavax to Prevent Shingles
MOR208 Named a “Breakthrough Therapy” in Some Lymphoma Cases
Ingrezza Given Orphan Drug Status for Tourette Syndrome in Young
FDA Slams Magellan Diagnostics for Lead Testing Violations
Biosimilars Could Cut U.S. Health Tab by $54 Billion in a Decade
African-Americans Die Younger Due to Heart Disease, Stroke
Easier-to-Use Formulation of Bydureon Wins FDA’s Blessing
FDA Approves Shingles Vaccine With More Than 90% Efficacy
Simponi Aria Approved for Psoriatic Arthritis, Ankylosing Spondylitis
Keytruda Doubles Lung Cancer Survival in Patients With High PD-L1
Nonopioid Drug Helps Migraines More Than Opioids, Study Shows
Imprimis to Offer Compounded Alternative to Restasis
Anthem to Launch New Pharmacy Benefits Manager
FDA Approves Yescarta, First CAR T-Cell Therapy for Lymphoma
Cascade of Costs Could Push Gene Therapy Over $1 Million Per Patient
Study: Emergency Rooms Provide Nearly Half of Medical Care
U.S. Judge Invalidates Allergan Patents on Restasis
Marino Withdraws From Consideration as U.S. Drug Czar
Stelara Approved for Use in Adolescents With Plaque Psoriasis
FDA Clears Robotically-Assisted Surgical Device for Adults
Cabozantinib Improves Survival in Advanced Liver Cancer
Trial Shows Strong Response to Lorlatinib in NSCLC Patients
FDA Clears First 7T Magnetic Resonance Imaging Device
NIH, Big Pharma Launch Cancer Immunotherapy Drive
Pfizer Weighs “Strategic Alternatives” for Consumer Healthcare Business
Vaccine Receives Orphan Drug Designation for Brain Cancer
Lilly Dealt a Setback by Phase 3 Lung Cancer Results
Study Finds Few Medicare Limits on Prescription Opioids
Penicillin Misconceptions May Lead to Surgical Infections
Tagrisso Termed Breakthrough Therapy as Initial Lung Cancer Treatment
SenTiva Approved for Treatment of Epilepsy
FDA Approves Implantable Sleep Apnea Treatment
Zilretta Approved for Osteoarthritis Knee Pain
FDA Approves First Zika Screening Test for Blood Donations
DNA-Based Zika Vaccine Safe, Effective in Phase 1 Testing
Antibiotic Susceptibility Testing in 30 Minutes or Less?
U.S. Appeals Court Reverses Ban on Praluent Sales
Mylan’s Generic of Copaxone Receives FDA Approval
Study: Sepsis Care Initiatives May Increase C. Difficile Rates, Antibiotic Resistance
Study: Patient Expectations Influence Effectiveness of SSRI Antidepressants
Antifungal Drug Candidate Receives Second QIDP Designation
Cancers Associated With Excess Weight Make Up 40% of U.S. Cancer Cases
Oxford Team to Test First Universal Flu Vaccine
Merck Becomes Latest to Drop HCV Development Programs
FDA Gives Adcetris Breakthrough Therapy Status as Firstline Hodgkin’s Treatment
FDA Seeks to Reduce Hurdles for Complex Generic Drug Development
